




aln collaboration with Medlmmune Limited, a wholly owned subsidiary of AstraZeneca PLC. As

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

<sup>\*&#</sup>x27;Regulatory submission' indicates US and/or EU submission unless other country/region is indicated under Area of Research.





For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.


<sup>\*&#</sup>x27;Regulatory submission' indicates US and/or EU submission unless other country/region is indicated under Area of Research.

<sup>&</sup>lt;sup>a</sup>Filing for regulatory approval based on pivotal phase II data. <sup>b</sup>In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC. AstraZeneca PLC. III MedImmune


cln collaboration with Juno Therapeutics. Juno Celgene has commercial rights outside of North America and China.

din collaboration with Acceleron Pharma. Acceleron

REVLIMID® and ISTODAX® are registered trademarks of Celgene Corporation. PPM<sup>TM</sup> is a trademark of Celgene Corporation.









<sup>a</sup>Under co-development option with AbbVie. <sup>b</sup>In collaboration with Acceleron Pharma. 

ACCELERON
OTEZLA® is a registered trademark of Celgene Corporation.

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

<sup>\*&#</sup>x27;Regulatory submission' indicates US and/or EU submission unless other country/region is indicated under Area of Research.